文献速递肿瘤 PET/CT神经核医学

脑MRI与18F-DOPA PET/CT不匹配:对EGFR突变肺腺癌长期生存者管理的影响

Mismatch Between Brain MRIs and 18 F-DOPA PET/CT : Impact on the Management of a Long Survivor With EGFR-Mutated Lung Adenocarcinoma.
PubMed 文献 · Clin Nucl Med · 2024-02-09

一例晚期肺腺癌患者接受厄洛替尼4年后,因左小脑脑转移行立体定向放疗,14个月后疑似局部复发并经18F-DOPA PET确认,另见3处摄取增高但MRI无明确病理信号,遂行第二程放疗。一年后3T MRI疑似孤立局部复发伴可疑18F-DOPA摄取,另见5处18F-DOPA摄取增高,其中1处在两次PET间增高;因MRI与PET不匹配,作者选择将厄洛替尼换为奥希替尼而非手术。

要点

  • 脑MRI与18F-DOPA PET/CT对脑转移复发判断不一致时,PET可检出MRI无明确病理信号的摄取灶。
  • 本例因MRI与PET不匹配,作者选择从厄洛替尼换为奥希替尼而非手术。
  • 18F-DOPA PET可在两次检查间显示部分摄取灶的动态变化。

核心结论

  • 作者报告了一例EGFR突变肺腺癌长期生存者脑MRI与18F-DOPA PET/CT不匹配的病例,并据此将厄洛替尼换为奥希替尼而非手术。

研究设计与样本

  • 本文为病例报告,报告一例接受厄洛替尼4年的晚期肺腺癌男性患者。

主要发现

  • 患者接受厄洛替尼4年后,因左小脑脑转移行立体定向放疗,14个月后疑似局部复发并经18F-DOPA PET确认,另描述3处摄取增高但MRI无明确病理信号,遂行第二程放疗。
  • 第二程放疗一年后,3T MRI疑似孤立局部复发伴可疑18F-DOPA摄取,另描述5处18F-DOPA摄取增高,其中1处在两次PET之间增高。
  • 因MRI与PET不匹配,作者选择将厄洛替尼换为奥希替尼而非手术。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

After receiving erlotinib for 4 years, a man with advanced lung adenocarcinoma was treated with stereotactic radiotherapy for a left cerebellar brain metastasis. Local relapse of the metastasis was suspected 14 months after and confirmed on 18 F-DOPA PET. Three additional uptakes were described with no unequivocal MRI pathological signal. A second radiotherapy course was delivered. One year later, isolated local recurrence was suspected on a 3 T MRI, with a suspicious 18 F-DOPA uptake. Five additional 18 F-DOPA uptakes were described among which one increased between the 2 PETs. Because of these MRI/PET mismatches, a switch from erlotinib to osimertinib was preferred over surgery.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Bourbonne V, Dissaux B, Seizeur R, et al. Mismatch Between Brain MRIs and 18 F-DOPA PET/CT : Impact on the Management of a Long Survivor With EGFR-Mutated Lung Adenocarcinoma. Clin Nucl Med. 2024. PMID: 38350083. doi:10.1097/RLU.0000000000005058

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。